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Abstract
Background: Many European citizens are seeking complementary and alternative medicine (CAM). These treatments
are regulated very differently in the EU/EFTA countries. This may demonstrate differences in how risk associated with
the use of CAM is perceived. Since most CAM treatments are practiced fairly similarly across Europe, differing risk
understandings may influence patient safety for European CAM users. The overall aim of this article is thus to
contribute to an overview and awareness of possible differing risk understandings in the field of CAM at a
policymaking/structural level in Europe.
Methods: The study is a re-analysis of data collected in the CAMbrella EU FP7 document and interview study on
the regulation of CAM in 39 European countries.
The 12 CAM modalities included in the CAMbrella study were ranked with regard to assumed risk potential depending
on the number of countries limiting its practice to regulated professions. The 39 countries were ranked according to
how many of the included CAM modalities they limit to be practiced by regulated professions.
Results: Twelve of 39 countries generally understand the included CAM treatments to represent “high risk”, 20 countries
“low risk”, while the remaining 7 countries understand CAM treatments as carrying “very little or no risk”. The
CAM modalities seen as carrying a risk high enough to warrant professional regulation in the highest number of
countries are chiropractic, acupuncture, massage, homeopathy and osteopathy.
The countries understanding most of the CAM modalities in the study as potentially high-risk treatments are with
two exceptions (Portugal and Belgium) all concentrated in the southeastern region of Europe.
Conclusion: The variation in regulation of CAM may represent a substantial lack of common risk understandings
between health policymakers in Europe. We think the discrepancies in regulation are to a considerable degree
also based on factors unrelated to patient risk. We argue that it is important for patient safety that policy makers
across Europe address this confusing situation. This could be done by applying the WHO patient safety definitions and
EU’s policy to facilitate access to “safe and high-quality healthcare”, and regulate CAM accordingly.
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Background
Many European citizens are seeking a broader spectrum
of treatment modalities [1–4]. This includes complemen-
tary and alternative medicine (CAM), also when offered
outside their national health care system. Users of CAM
mostly perceive CAM products and treatments as safe,
while health care professionals often express a strong
opinion that CAM treatments put patients at risk [5–7].
The World Health Organization (WHO) and the
European Union (EU) have both emphasized that the
first “rule” of health care is to “not harm” the patient.
The WHO patient safety programme states that “the
simplest definition of patient safety is the prevention of
errors and adverse effects to patients associated with
health care” [8]. This understanding underpins all regu-
lation of health care, both of professionals and products,
and is taken for granted in the 2011/24/EU Directive “on
the application of patients’ rights in cross-border health-
care”. This directive aims to facilitate access to “safe and
high-quality healthcare” for European citizens [9], and
patients need to be confident that the treatments offered
fulfill these conditions.
Regulation of health services is a risk governance tool
for health authorities. The European Union (EU) as-
sumes that a “safe and high quality healthcare” is
dependent on a harmonized level of legislation and regu-
lation [9]. The regulation of health care services is not
included in the EU Treaty [10] or the 2006/123/EC dir-
ective on services in the internal market [11]. The EU
Commission has, however, passed the Information docu-
ment “Conclusions on Common values and principles in
European Union Health Systems” to support the EU
Member states in their regulation of health care services
[12]. The Commission expects that a common set of
operating and regulation principles will strengthen
“Quality, Safety, Patient involvement and Redress” [12].
Further, the EU Commission emphasizes that regulation
of health care must include standardization of treat-
ments and education, recognizable and transparent le-
gislation in all countries, standardized clinical and
professional training, together with involvement of pa-
tients in their treatment. From a patient safety perspec-
tive, the EU Commission promotes regulation of health
care as an important governance tool to reduce risk and
facilitate high quality health care services for all
European citizens.
A large study [13] recently documented that “CAM in
Europe is not regulated in accordance with current
theory dealing with risk governance, risk regulation and
patient safety.” In addition, the regulation does not seem
to be based on consensual scientific knowledge on
effects and risks in CAM practices, efficient risk
management in health care governance or systematic
reports of harmful events [5, 13–15]. As a result of this
apparent lack of common risk understanding, CAM is
regulated “either as conventional, complementary or al-
ternative medicine, or not regulated at all” [13, 16, 17].
Since the treatments themselves are practiced fairly
similarly across Europe, this possible differing risk un-
derstandings could influence patient safety for European
CAM users.
The overall aim of this article is thus to contribute to
an overview and awareness of possible differing risk un-
derstandings in the field of CAM at a policymaking/
structural level in Europe.
The specific research question is:
Which risk understandings may be derived from the
current regulation of CAM in 39 European countries?
Methods
This study is a re-analysis of data collected in the
CAMbrella EU FP7 document and interview study on
CAM regulation in Europe [13, 16, 17]. Data dealing
with the general legal and regulatory status of CAM on
the first and second national legal level, including 12
specific CAM treatment modalities and CAM providers/
professions, were collected from the European Union
(EU) and 39 European countries. The included CAM
modalities were acupuncture, anthroposophic medicine,
ayurvedic medicine, chiropractic, herbal medicine/phy-
totherapy, homeopathy, massage, naprapathy, naturop-
athy, neural therapy, osteopathy and Traditional Chinese
Medicine (TCM).
The 12 CAM modalities included in the CAMbrella
study were in this study ranked with regard to assumed
risk potential depending on the number of countries
limiting practice of CAM modalities to regulated profes-
sions. We ranked the 39 countries according to how
many CAM modalities they limit to regulated profes-
sions. We have arbitrarily classified countries limiting 5
or more of 12 CAM modalities to regulated professions
as seeing CAM as high-risk treatment approaches, and
regulating 1–4 as seeing CAM as carrying a potential
low patient risk. If a country has not limited any modal-
ity to a regulated profession, we classify the country as
seeing CAM with very little or no risk.
Results
We found that 12 countries understand the included
CAM treatments as carrying a high risk, 20 understand
the CAM treatments to have low risk, while the
remaining 7 countries generally understand the CAM
treatments to be with very little or no risk (Fig. 1). We
also found that countries understanding CAM to be
associated with low, very little or no risk, only regulate
modalities that are the most commonly regulated in the
countries with a high-risk understanding. There are,
Wiesener et al. BMC Complementary and Alternative Medicine  (2018) 18:11 Page 2 of 7
Fig. 1 European country specific regulation of 12 CAM modalities-risk understanding
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however, two country exceptions worth noting; Finland
and Sweden also regulate naprapaths.
The CAM modalities seen as carrying a risk high
enough to warrant professional regulation in the highest
number of countries are chiropractic, acupuncture,
massage, homeopathy and osteopathy. The “manual”
therapies (naprapathy, massage, osteopathy and chiro-
practics) are almost exclusively regulated as specific
health professions with protected titles in the countries
that have chosen to regulate.
The countries that seem to understand CAM treat-
ment to be associated with a potentially high patient risk
are not randomly distributed across Europe. With two
exceptions (Portugal and Belgium), they are all concen-
trated in the southeastern region of Europe (Fig. 2).
Discussion
This study demonstrates that the regulation of CAM indi-
cates the differences in how the European health author-
ities may perceive risk associated with the use of CAM.
We do not extrapolate our findings beyond the 39
countries studied, and there is therefore no selection
bias in this study with regard to countries. The
Fig. 2 Risk understanding-number of regulated CAM professions. “Risk understanding-number of regulated CAM professions” depicted in Figure 2 has
been developed by the authors and has not been published before. The map is developed on the basis of an uncolored clip-art map of the European
countries, retrieved from: “Bruce Jones design Inc. 2006-www.bjdesign.com”. The clip-art map was purchased first time for use by NAFKAM in the
CAMbrella project FP7-HEALTH-2009, GA No.241951. NAFKAM allows the authors to develop maps using this purchased clip-art
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procedure followed to gain overview of the regulatory
situation was comprehensive [13, 16, 17], and the regula-
tion in each country is constantly being updated [18].
To our information, no one has successfully contested
our descriptions, and the information presented is there-
fore likely to be unbiased.
To our knowledge, no one has previously described
international CAM regulation in a risk perspective
focusing on risk understanding.
In the introduction to the 2011/24/EU Directive “on the
application of patients’ rights in cross-border healthcare”,
the European Council assumes that “safe and high-quality
healthcare” is in place when declaring that there “is a set
of operating principles that are shared by health systems
throughout the Union” (Directive 2011/24/EU Directive-
introduction note 5) [9]. The most common used
“operating principles” in providing safe and high-quality
healthcare are to regulate the professional requirements of
health providers and standardization of treatments [13].
Baldwin claims that “..regulation is often thought of as an
activity that restricts behavior and prevents the occurrence
of certain undesirable activities” [19].
Previous studies show that conventional healthcare is
regulated quite similarly across Europe. Core health pro-
fessionals are defined as “Sectorial professions” benefit-
ing from automatic recognition on the basis of
harmonization of minimum training conditions (doctors,
nurses, midwives, pharmacists and dentists) [13, 20].
High quality and safety are perceived as established
through appropriate research and sound professional
standards, at the same time as attractive treatment
options across borders are available [21].
We would have expected to find similar sets of operat-
ing principles in the regulation of CAM. The most regu-
lated CAM modality in Europe is chiropractic. Does this
mean that chiropractic treatment is associated with such
a high patient risk that 25 European countries see strong
regulation as necessary, or could the regulation be based
on other criteria as well? A closer look at the process of
regulating chiropractors in Norway in 1988 sheds light
on this possibility [22]. The decision to regulate was
based on a 1985 governmental report. The arguments
for giving chiropractors authorization and a protected
title were to secure the educational requirements for
practicing chiropractic. The politicians stated that regu-
lation of chiropractors would strengthen the profession
and lead to recognition of the chiropractors as health
professionals, nothing about risk [23].
Taking acupuncture regulation as an additional ex-
ample, we found no consistent pattern of risk under-
standing. Acupuncture treatment is the second most
regulated CAM modality in Europe, but only 3 countries
have established “acupuncturist” as a profession. In
Hungary 3–5 years of acupuncture education/training at
a university level is required in addition to being a med-
ical doctor. In Norway acupuncture can be legally prac-
ticed without any educational requirements whatsoever.
Based on our classification, acupuncture is understood
to be a high-risk treatment in Hungary, while Norwegian
health authorities seem to understand the same treat-
ment to be without risk. The “high-risk” regulation in
Hungary could possibly be based on registered adverse
events, number of harmed patients and claims, com-
bined with risk or effect research. If so, why do they not
take into account this risk information in the “no-risk”
regulation in Norway?
An interesting example of risk understanding linked to
the importance of professional knowledge is the regulation
of homeopathy in Belgium. The “Belgian Healthcare
Knowledge Centre” stated in a public report in 2011 that
due to safety reasons, homeopathy should be restricted to
physicians, dentists and veterinary doctors [24]. Conse-
quently, “The Belgian Council of Ministers passed new
regulation on homeopathy in 2013, made official by a
Royal Decree published 12 May 2014 by the Ministry of
Health” [18]. This decision is consistent with Belgian regu-
lation of other common CAM practices (Fig. 1 European
country specific regulation of 12 CAM modalities-risk un-
derstanding). We hypothesize that the risk perception of
the Belgian health authorities is of an “indirect” nature.
Regulation of CAM- a decision model
Risk associated with health care is often separated into
direct risk caused by the treatment itself or indirect risk
related to adverse effects of the treatment context [15].
The discrepancies in regulatory practice between coun-
tries are, in our view, only explicable if factors other
than direct or indirect risk are taken into consideration.
Based on the regulation status across Europe, as well as
established risk and health management research and le-
gislation, we have developed a theoretical decision model
we think more truly reflects the political process relevant
for the regulation of CAM (Fig. 3).
The model includes multiple factors that come into
play when a country considers the regulation of CAM,
and the chosen level of regulation will reflect the factors
given most importance.
The map showing CAM regulation presented in this
article (Fig. 2) illustrates the potential importance of na-
tional and/or regional traditions. This was already
suggested by Gerd Ersdal 12 years ago [25]. She divided
European countries into “all-regulated” and “semi-regu-
lated” systems of CAM regulation, and suggested that
this geographical megapattern seemed to indicate that in
the middle and south of Europe CAM regulation
followed the principle: “if regulated-it is allowed”. In
northern Europe the principle “if not forbidden by law-
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it is allowed” seemed to dominate. But even within these
regions the regulations of CAM varies substantially. It is
difficult to understand the basis for why they have
regulated the way they have done.
Conclusion
The variation in regulation of CAM may represent a
substantial lack of common risk understandings between
health policymakers in Europe. We think the discrepan-
cies in regulation are to a considerable degree also based
on factors unrelated to patient risk. We argue that it is
important for patient safety that policy makers across
Europe address this confusing situation. This could be
done by applying the WHO patient safety definitions
and EU’s policy to facilitate access to “safe and high-qu-
ality healthcare”, and regulate CAM accordingly.
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